Juvabis designs next-generation antibacterial therapeutics that withstand mechanisms of bacterial drug-resistance and at the same time display superior tolerability due to increased target selectivity by rational design. Juvabis has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates discovered in collaboration with researchers at the ETH Zurich and Wayne State University in Detroit.